Abstract:Abstract Background Upadacitinib (UPA), an oral Janus kinase inhibitor approved for the treatment of moderately to severely active Crohn’s disease (CD), demonstrated significantly higher rates of endoscopic response and remission compared with placebo (PBO) in the phase 3 induction (U-EXCEL, U-EXCEED) and maintenance (U-ENDURE) trials.1 Improvements in the narrowing component of BL stenoses with UPA have been previously reported.2 This analysis evaluated changes in the individual components of the Simple Endoscopic Score for CD (SES-CD) among patients treated with UPA vs PBO. Methods Data were pooled from the two induction phase 3 studies evaluating patients who received PBO or UPA 45 mg (UPA45) once daily (QD) for 12 weeks. Patients who achieved clinical response to 12 weeks of UPA45 were re-randomised in the U-ENDURE maintenance study to receive PBO, UPA 15 mg (UPA15) QD, or UPA 30 mg (UPA30) QD for 52 weeks. This analysis evaluated the mean changes from baseline (BL) in total SES-CD and four individual components (size of ulcers, ulcerated surface, affected surface, presence of narrowing), as well as improvements by disease location and prior biologic failure (bio-failure) status. Results Mean [SD] total SES-CD at BL was similar across treatment groups (induction: PBO 13.9 [7.5], UPA45 14.6 [7.7]). In the overall population, mean [SD] changes from BL in total SES-CD were greater with UPA45 (–6.8 [7.6]) vs PBO (–0.5 [5.7]; P < .0001) at week 12, and at week 52 with UPA15 (–9.9 [8.6]) and UPA30 (–10.3 [8.1]) vs PBO (–2.4 [5.0]; all P < .0001; Figure 1A). Similar results were observed for patients with ileocolonic and colonic disease at week 12 and week 52 (Figure 1A). For patients with prior bio-failure, mean changes from BL in total SES-CD were greater with UPA45 (–6.6 [7.9]) vs PBO (0.0 [5.8]; P < .0001) at week 12, and with UPA15 (–10.4 [9.4]) and UPA30 (–9.7 [7.2]) vs PBO (–2.8 [4.8]; all P < .0001) at week 52; similar findings were reported for patients without prior bio-failure. At week 12 and week 52, treatment with UPA resulted in greater improvements vs PBO in the individual SES-CD components of size of ulcers, ulcerated surface, and affected surface, but not for the presence of narrowing (Figure 1B). Conclusion In patients with moderately to severely active CD, UPA induction and maintenance treatment vs PBO improved total SES-CD, irrespective of prior bio-failure. The changes were driven by the SES-CD components of the size of ulcers, ulcerated surface, and affected surface. When evaluated by disease location, appreciable improvements occurred in patients with ileocolonic and colonic CD, as compared to ileal disease. References: 1. Loftus, E. V. et al. N. Engl. J. Med. 2023;388,1966–80 2. Reinisch, W. et al. UEGW 2023. MP005 [Poster]

Achievement of Endoscopic Remission After Induction Reduces Hospitalization Burden in Crohn's Disease: Findings From a Pooled Post Hoc Analysis of Risankizumab and Upadacitinib Phase III Trials

Maintenance Risankizumab Sustains Induction Response in Patients with Crohn's Disease in a Randomized Phase 3 Trial.

OP25 Patients with Moderate to Severe Crohn’s Disease with and Without Prior Biologic Failure Demonstrate Improved Endoscopic Outcomes with Risankizumab: Results from Phase 3 Induction and Maintenance Trials

Shorter Crohn's Disease Duration Is Associated With Better Clinical and Endoscopic Outcomes With Risankizumab in Phase 3 Studies

P741 Characterisation of endoscopic improvements with risankizumab treatment in patients with moderately to severely active Crohn’s disease

S1472 Efficacy of Risankizumab Maintenance Therapy by Clinical Remission and Endoscopic Improvement Status in Patients With Moderately to Severely Active Ulcerative Colitis: Post Hoc Analysis of the COMMAND Phase 3 Study

Induction of Endoscopic Response, Remission, and Ulcer-Free Endoscopy With Upadacitinib Is Associated With Improved Clinical Outcomes and Quality of Life in Patients With Crohn's Disease

Risankizumab Versus Ustekinumab for Moderate-to-Severe Crohn’s Disease

P623 Network meta-analysis to evaluate the comparative efficacy of advanced therapies as first line for maintenance treatment of adult patients with moderate-to-severe Crohn’s disease

P927 Long-term outcomes of risankizumab in Crohn’s disease: a multicenter GETAID Study

P862 Effects of induction and maintenance therapy with risankizumab on health-related quality of life outcomes in patients with moderately to severely active ulcerative colitis: A post-hoc analysis of Phase 2b/3 trials

P848 Risankizumab Effectiveness in Ustekinumab-naïve and Ustekinumab-experienced Patients with Crohn’s Disease- Real-world Data from a Large Tertiary Center

Efficacy of Induction Upadacitinib Therapy in Chinese Patients with Moderately to Severely Active Crohn's Disease

DOP47 Characterisation of endoscopic improvement in Crohn’s Disease with upadacitinib treatment

DOP18 Efficacy of risankizumab versus ustekinumab by baseline Crohn’s Disease location: post-hoc analysis of the SEQUENCE head-to-head trial

Efficacy and Safety of Risankizumab for Crohn's Disease in Patients from Asian Countries: a Post Hoc Subanalysis of the Global Phase 3 ADVANCE, MOTIVATE, and FORTIFY Studies.

P756 Efficacy and safety of medical therapies for maintenance of surgically induced remission in Crohn’s disease: A systematic review and network meta-analysis

Efficacy and safety of risankizumab by baseline corticosteroid use and achievement of corticosteroid‐free clinical and endoscopic outcomes in patients with moderately to severely active Crohn's disease

P330 Ultrasound remission after biologic induction predicts long-term endoscopic remission in Crohn’s disease

DOP10 Risankizumab Versus Ustekinumab for the Achievement of Endoscopic Outcomes in Patients With Moderate-to-Severe Crohn’s Disease: Results From the Phase 3b SEQUENCE Trial

Real-world Effectiveness and Safety of Risankizumab in Patients with Moderate to Severe Multirefractory Crohn’s Disease: A Belgian Multicentric Cohort Study